H.C. Wainwright raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $24 from $22 and keeps a Buy rating on the shares. The company reported a “beat and raise” Q2, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL: